分子靶向药物在晚期NSCLC患者中的疗效探讨

Efficacy of targeted drugs in the treatment of patients with advanced NSCLC

目的探析单抗类分子靶向药物在晚期非小细胞肺癌(NSCLC)患者化疗治疗期间的临床应用价值。方法分析2014年2月至2015年12月在我院接受治疗的NSCLC患者的临床资料。根据治疗方案的不同,将入选者分为观察组(化疗+单抗类分子靶向药物)和对照组(化疗)两组。比较两组患者的基线资料、临床疗效、临床特征(包括表皮生长因子受体EGFR、癌胚抗原CEA以及癌抗原125)以及不良反应发生率。结果本研究共入组患者72例,其中观察组和对照组各36例。两组患者的基线资料无显著差异(P>0.05)。观察组患者的临床有效率(86.1%)明显高于对照组(52.8%)(P<0.01)。两组患者治疗前的临床指标(包括CA125、CEA、EGFR)水平无显著差异(P>0.05),而治疗后观察组患者的CA125、CEA、EGFR的表达水平均明显低于对照组(P<0.01)。观察组患者的不良反应发生率(5.6%)明显低于对照组(22.2%)(P<0.05)。结论接受化疗治疗的晚期NSCLC患者添加使用单抗类分子靶向药物进行治疗的疗效更加确切,且不良反应发生率更低,值得临床推广。

Objective To analyze the clinical value of monoclonal antibody targeted drugs in the treatment of patients with advanced NSCLC during chemotherapy .Methods The clinical data of patients with NSCLC received treatment at our hospital from February , 2014 to December , 2015 was retrospectively analyzed , and they were divided into two groups according to the treatment , the observation group （ chemotherapy ＋monoclonal antibody targeted drugs） and the control group （chemotherapy）.The general information, clinical curative effect, clinical features （including EGFR, CEA and CA125） and the adverse reactions were observed .Results A total of 72 patients were retrospective analyzed , including 36 in the observe group and 36 in the control group .The general information had no statistical difference between the two groups （P〉0.05）.The clinical efficiency was obviously higher in the observa-tion group （86.1%） than in the control group （52.8%） （P〈0.01）.Before the treatment, there was no significant difference in EGFR, CEA and CA125 between the two groups （P〉0.05）.After the treatment, the levels of EGFR, CEA and CA125 in the observation group were obviously higher than those in the control group （ P〈0.01 ） .The incidence of adverse reactions was obviously lower in the observation group （ 5.6%） than in the control group （22.2%） （P〈0.05）.Conclusion The clinical efficacy of monoclonal antibody targeted drugs has certain curative effect in the treatment of patients with advanced NSCLC during chemotherapy , and the incidence of adverse reactions is lower, which is worthy of wide promotion .